Funding Barriers Slow Regenerative Medicine Progress

D

Doctor's Pharmacy podcast by Mark Hyman, MD featuring Dr. Adeel Khan

Quotes From Source

“NIH grants insufficient for costly clinical trials.”

Story of claim

Dr. Adeel Khan highlights how insufficient NIH funding and strict regulations impede clinical trials for regenerative medicine, necessitating venture capital for research advancement.

  • Goal: Secure adequate funding and overcome regulatory hurdles to advance regenerative medicine.
  • Proof: NIH grants alone are insufficient for costly trials; venture capital is critical for progress.
  • Nuances:
    • 3D bioprinting company received $18 million NIH grant.
    • Regenerative medicine companies struggle to find funding.
  • Impact on Life: Research advancements could lead to innovative treatments becoming more accessible, improving patient outcomes.

Investments

  • Price: Research funding needed exceeds $20 million
  • Time: Years of research and trials required
  • Effort: Intense effort needed to secure funding and navigate regulations

Risks

Financial and regulatory barriers may delay treatment innovations.

Alternatives

  • Collaborative global research partnerships
  • Crowdfunding for specific regenerative projects

Get Started 🚀

  • Engage with biotech investors for venture capital.
  • Lobby for increased NIH funding.
  • Collaborate with international research institutions.

Brogevity AI can make mistakes. Check important info.

Reference Video